Collaborative dementia care programs are effective in addressing the needs of patients with dementia and their caregivers. 3 key findings →
Participants: 780 Evidence: high
Full summary, score breakdown and related studies → Original source
Research
29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The inclusion criteria for peer-reviewed English publications from March 2020 to August 2022 consisted of studies related to telehealth services for people living with dementia and their family caregivers and studies conducted during the COVID-19 pandemic. 5 key findings →
Design: randomized controlled trial Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source
57/100
Choosing optimal P2Y12 inhibitor in frail older adults is challenging because they are at increased risk of both ischemic and bleeding events. 4 key findings →
Design: cohort study Participants: 11,239 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The sample included 2 619 464 patients (mean [SD] age, 81.3 [8.6] years; 61% women; 87% were White; 8% were Black; 22% with ADRD). 5 key findings →
Design: cross-sectional Participants: 464 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The average detection rates for mild cognitive impairment is 0.08 (interquartile range=0.00-0.02) for both clinicians and practices, suggesting that only about 8% of expected cases were diagnosed on average. 3 key findings →
Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 454,508 beneficiaries diagnosed with ADRD in 2017, 250,837 (55%) were in TM and 203,671 (45%) in MA. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
Prevalence studies indicate that as many as 50% of older adults experience bothersome pain on a regular basis (Dahlhamer et al., 2018; Galicia-Castillo & Weiner, 2023; Larsson et al., 2017; Lin et al., 2020; Rikard et al., 2023). 5 key findings →
Design: randomized controlled trial Participants: 2,041 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
To evaluate characteristics of Medicare beneficiaries associated with practices and clinicians offering telephone visits only and patients receiving telephone visits only, when both telephone and video were available. 5 key findings →
Participants: 1,593 Evidence: low
Full summary, score breakdown and related studies → Original source
54/100
In-hospital death among nursing home residents with dementia has been associated with poorer quality of end-of-life care. 5 key findings →
Design: systematic review Participants: 240,000 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
An estimated 2 971 449 individuals (mean age, 66.4 years; 95% CI, 64.8-68.2 years) filled prescriptions for OAB medications in 2019; 2 185 214 (73.5%; 95% CI, 62.6%-84.5%) identified as female, 2 326 901 (78.3%; 95% CI, 66.3%-90.3%) self-identified as non-Hispanic White, 260 685 (8.8%; 95% CI, 5.0%-12.5%) identified as non-Hispanic Black, 167 210 (5.6%; 95% CI, 3.1%-8.2%) identified as Hispanic, 158 507 (5.3%; 95% CI, 2.3%-8.4%) identified as non-Hispanic other race, and 58 147 (2.0%; 95% CI, 0.3%-3.6%) identified as non-Hispanic Asian. 5 key findings →
Design: cross-sectional Participants: 449 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lenore Ackerman *Correspondence: David Geffen School of Medicine, 10833 Le Conte Ave, Box 951738, Los Angeles, CA 90095-1738 telephone: 310-794-0206; E-mail Address: [email protected] https://orcid.org/0000-0003-4192-7649 Department of Urology and Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California View All Author Informationhttps://doi.org/10.1097/JU.0000000000003430AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Overactive bladder, including symptoms of increased urinary frequency, urgency, and incontinence, is more prevalent than diabetes, affecting 1 in 6 adults in the United States.1,2 Occurring more commonly among women and older adults, untreated overactive bladder is associated with reduced quality of life, increased incidence of depression and anxiety, increased risk of experiencing falls/fractures, and increased institutionalization. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
of 74,486 decedents (60.5% women; mean age 87.1 years (standard deviation: 7.1)), 82.6% had at least one ED visit in their last year of life. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The 32 796 872 Medicare beneficiaries in the cohort had a mean (SD) age of 74.0 (12.5) years and included 18 228 513 females (55.6%). 5 key findings →
Design: cross-sectional Participants: 18 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this cross-sectional study of the Medicare population with acute and postacute care use, beneficiaries with ADRD had increasing enrollment in the Medicare Advantage program, proportional to the growth in overall enrollment, but their disenrollment from Medicare Advantage in the following year remained higher compared with beneficiaries without ADRD. 4 key findings →
Design: cross-sectional Participants: 18 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This cohort study examines rates of new diagnosis of Alzheimer disease and related dementias among beneficiaries of Medicare Advantage plans vs traditional Medicare from 2016 through 2020. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The neurodegenerative disease field has enjoyed extremely limited success in the development of effective therapeutics. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Use of pharmacological treatments is one possible modifiable risk factor for cognitive disorders. 5 key findings →
Design: case-control study Participants: 282,858 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
To ensure diversity, we developed a comprehensive recruitment strategy using a diverse, culturally‐trained staff that includes : • Identifying Dementia Specialists experienced recruiting minorities • Embedding high‐impact community engagement in select regions • Increasing capacity of specialists and PET facilities to engage minorities • Increasing pipeline of referrals to Dementia Specialists • Creating a culturally‐informed awareness campaign Result New IDEAS has enrolled 4,524 participants including 954 (21.1%) Black/African American, and 842 (18.6%) Hispanic/Latinx. 3 key findings →
Design: cohort study Participants: 4,524 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Many studies have examined factors associated with individuals of high or low healthcare spending in a given year. 5 key findings →
Design: longitudinal study Participants: 30,729 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 145 342 adults met inclusion criteria; 10.5% had ADRD and were likely to be older, female, and have more comorbid conditions. 4 key findings →
Participants: 342 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The most important predictors of having a diagnosis of ADRD by the start of care OASIS assessment were a prior discharge diagnosis of ADRD among those admitted from an inpatient setting, and frequently exhibiting symptoms of confusion. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
PLWD proactively enrolled in a dementia care program have high baseline rates of behavioral issues and their caregivers have elevated depression and stress scores. 2 key findings →
Design: longitudinal study Participants: 195 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Diagnostic pathways for patients presenting with cognitive complaints may vary across geographies. 1 key finding →
Design: cross-sectional Participants: 6,744 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 4505 respondents aged ≥70 years, 1750 (38.8%) had possible or probable dementia and 2755 (61.2%) had no dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Approximately half of Medicare beneficiaries are enrolled in Medicare Advantage (MA), a private plan alternative to traditional Medicare (TM). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →